华泰联合证券有限责任公司 关于北京英诺特生物技术股份有限公司 2023 年度募集资金存放和使用情况专项核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作 为北京英诺特生物技术股份有限公司（以下简称"英诺特"或"公司"）首次公开 发行股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求 （2022 年修订）》《上海证券交易所科创板股票上市规则（2023 年 8 月修订）》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法律 法规的规定，对英诺特在 2023 年度募集资金存放与使用情况进行了审慎核查， 核查情况及核查意见如下： 一、募集资金的基本情况 （一）首次公开发行股票募集资金情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2022 年 4 月 28 日作出的《关于同意北京英诺特生物技术股份有限公司首次公开发行股票注 册的批复》（证监许可[2022]902 号），并经上海证券交易所同意，公司于 2022 年 7月首次向社会公开发行人民币普通股（A 股）股票 34, ...

关于北京英诺特生物技术股份有限公司 华泰联合证券有限责任公司 变更及终止部分募投项目及募投项目延期的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作为 北京英诺特生物技术股份有限公司（以下简称"英诺特"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》及《上海证券交易所科创板上市公司自律监 管指引第 1 号——规范运作》等相关规定，对英诺特变更及终止部分募投项目及 募投项目延期的事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2022 年 4 月 28 日作出的《关于同意北京英诺特生物技术股份有限公司首次公开发行股票注册的 批复》（证监许可[2022]902 号），并经上海证券交易所同意，公司于 2022 年 7 月 首次向社会公开发行人民币普通股（A 股）股票 34,020,000 股，每股面值人民币 1.00 元，每股发行价为人民币 26.06 元，募集资金总额为人民币 88,656.12 万元， 扣除发行费用（含增值税，不含前期已 ...

证券代码：688253 证券简称：英诺特 公告编号：2024-009 北京英诺特生物技术股份有限公司关于召开 2023 年 度暨 2024 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京英诺特生物技术股份有限公司（以下简称"公司"）将于 2024 年 4 月 16 日发布公司 2023 年年度报告、2024 年第一季度报告，为便于广大投资者更全面 深入地了解公司经营成果、财务状况，公司计划于 2024 年 4 月 17 日（星期三） 上午 11:00-12:00 举行 2023 年度暨 2024 年第一季度业绩说明会，就投资者关心 的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年度、2024 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 披露允许的范围内就投资者普遍关注的问题进行回答。 1 / 3 会议召开时间：2024 年 4 月 17 日（星期三）上午 11:00-12:00 会议召开地点： ...

Investment Rating - The report maintains a "Buy" rating for the company [9][14]. Core Insights - The company is expected to achieve significant growth in Q1 2024, with projected revenue between RMB 257 million and RMB 285 million, representing a year-on-year increase of 91.06% to 111.88%. The net profit attributable to shareholders is anticipated to be between RMB 138 million and RMB 154 million, reflecting a growth of 156.42% to 186.15% [11]. - The company is intensifying its market expansion efforts, particularly in tiered hospitals and grassroots medical markets, with a notable increase in hospital coverage from approximately 1,700 in July 2022 to a significantly higher number in 2023 [12]. - Favorable policies and increased awareness of early diagnosis are driving demand for respiratory testing, supported by government initiatives and expert consensus on the importance of early screening for respiratory diseases [13]. Financial Summary - Revenue projections for 2023-2025 are RMB 478 million, RMB 660 million, and RMB 891 million, with corresponding net profits of RMB 175 million, RMB 281 million, and RMB 381 million. The expected EPS for these years are RMB 1.28, RMB 2.07, and RMB 2.80, respectively [15][16]. - The company’s current P/E ratios are projected to be 28.90, 17.95, and 13.26 for 2023, 2024, and 2025, indicating a favorable valuation trend [14][15].

[Table_StockNameRptType] 英诺特（ 688253） 公司研究/公司点评 [公司价格与沪深 Table_Chart] 300 走势比较 -32% -7% 19% 44% 69% 3/23 6/23 9/23 12/23 英诺特 沪深300 [Table_CompanyReport] 相关报告 ⚫[Table_Summary] 事件： 2024 年 3 月 31 日，英诺特发布 2024 年第一季度业绩预告，预计公司 2024 年第一季度实现营业收入 2.57-2.85 亿元，同比增长 91.06%-111.88%；归 母净利润 1.38-1.54 亿元，同比增长 156.42%-186.15%。 ⚫ 点评： | --- | --- | --- | --- | --- | |------------------------------------------------------|-------------------------|-------|------------------|-------------| | ⚫ [Tab 重要财务指标 le_Profit] \n主要财务指标 | ...

Investment Rating - The report maintains a "Buy-A" investment rating with a target price of 42.02 CNY, which corresponds to a dynamic price-to-earnings ratio of 20 times for 2024 [3][28]. Core Insights - The company is expected to achieve significant revenue growth, with projected increases of 7.0%, 36.8%, and 53.4% in operating income from 2023 to 2025. Non-COVID related business revenue is forecasted to grow by 205.5%, 57.1%, and 53.4% during the same period [3][4]. - The first quarter of 2024 is anticipated to see operating income between 257 to 285 million CNY, representing a year-on-year growth of 91.06% to 111.88%. The net profit is expected to be between 138 to 154 million CNY, reflecting a growth of 156.42% to 186.15% [11][27]. - The company has developed several exclusive multi-detection products, enhancing its market presence in pediatric emergency departments and expanding its coverage in hospitals [30]. Financial Performance - The company's main revenue is projected to grow from 478.02 million CNY in 2023 to 1,002.92 million CNY by 2025. Net profit is expected to rise from 174.76 million CNY in 2023 to 424.72 million CNY in 2025 [4][3]. - The net profit margin is projected to improve significantly, reaching approximately 53.87% in Q1 2024, marking a historical high for non-COVID business [11][30]. - The company has a strong return on invested capital (ROIC) forecasted at 58.34% by 2025, indicating robust profitability [4]. Market Dynamics - The demand for respiratory pathogen testing remains high, with a notable increase in flu case monitoring compared to the previous year. The report highlights that the awareness and acceptance of pathogen testing have significantly improved post-COVID [27][15]. - The regulatory environment is supportive, with multiple directives from the National Health Commission emphasizing the necessity of pathogen detection and multi-detection testing [12][15].

证券代码：688253 证券简称：英诺特 北京英诺特生物技术股份有限公司 投资者关系活动记录表 编号：2024-005 £特定对象调研 □分析师会议 □媒体采访 投资者关系活 □业绩说明会 □新闻发布会 路演活动 动类别 □现场参观 其他（券商策略会） 嘉实基金：郝淼、孙晓晖、夏国强；信达澳亚基金：王建华、李东升、张 旻；广发基金：梁东旭、李善欣、邱世磊；泰康资产：陈璟、颜媛；磐耀 资产：孙智超；中邮保险：王晓博；泓澄投资：殷萌；平安基金：张淼； 长盛基金：洪靖怡；英大资产：卫雯清；中泰资管：高兰君；新华资产： 参与单位名称 李浩；中信建投：刘慧彬；中信建投：王在存；国投瑞银：肖汉山；博时 及人员姓名 基金：张涵；安信基金：徐衍鹏；华宝基金：张金涛；兴业基金：裘若 桑；东方基金：王芳玲；太平养老：张翼；陆家嘴信托：胡瑞丽；农银基 金：梦圆；鹏华基金：蔡春根；睿亿投资：许锋；中欧：田川、任逸哲； 兴证全球：戴心、隋毅、谢长雁；华泰柏瑞：邹丽晴、丁志远、陈乐；国 寿资产：邓文强；国新国证：赵起鹤；鹏扬基金：任宵逸、崔洁铭。 时间 2024年3月13日至2024年3月19日 地点 网络会议、券商策略会 上市公司 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [9]. Core Insights - The company has significant growth potential in respiratory pathogen detection, with a target population of 400 million susceptible individuals, including infants, children, and the elderly. The market for diagnostic differentiation is expected to expand as patient and physician awareness increases [6][10]. - The company has experienced rapid growth since 2021, with a compound annual growth rate (CAGR) of 36.4% in revenue from 2019 to 2023, reaching an estimated revenue of 478 million yuan in 2023. The net profit for the same period has a CAGR of 59.4%, with an expected net profit of 175 million yuan in 2023 [10][46]. - The company is a leader in the domestic respiratory pathogen detection market, having developed a comprehensive product line since 2011, with over 15 types of respiratory pathogens covered and a significant number of product registrations both domestically and internationally [10][52]. Summary by Sections Market Performance - The company's stock price closed at 36.00 yuan, with a 52-week price fluctuation between 19.12 and 38.25 yuan. The total market capitalization is approximately 4.898 billion yuan [4]. Financial Performance - Revenue is projected to grow from 478 million yuan in 2023 to 625 million yuan in 2024, and further to 828 million yuan in 2025, with year-on-year growth rates of 30.7% and 32.4% respectively. The gross margin is expected to stabilize around 58.9% to 59.1% during this period [7][62]. - The earnings per share (EPS) are forecasted to be 1.90 yuan in 2024 and 2.52 yuan in 2025, reflecting a strong growth trajectory [11][62]. Product and Market Expansion - The company is expanding into international markets, particularly in Southeast Asia, where it has established a headquarters in Singapore. The demand for quality POCT products in respiratory pathogen detection is growing rapidly in these regions [11]. - The company has a diverse product matrix, including various rapid detection kits for respiratory pathogens, and is also expanding into other diagnostic areas such as digestive health and hepatitis [25][44]. Industry Context - The respiratory pathogen detection market is expected to grow significantly, driven by increased awareness and demand for rapid testing solutions post-COVID-19. The global respiratory disease testing market is projected to grow from 5.59 billion USD in 2023 to 6.72 billion USD by 2028, with a CAGR of 3.77% [68]. - The competitive landscape in the respiratory pathogen detection industry is fragmented, with the company holding a market share of approximately 12.4% as of 2019, indicating a strong position among a variety of competitors [70].

证券代码：688253 证券简称：英诺特 北京英诺特生物技术股份有限公司 投资者关系活动记录表 编号：2024-004 特定对象调研 □分析师会议 □媒体采访 投资者关系活 □业绩说明会 □新闻发布会 路演活动 动类别 □现场参观 □其他（） 新华资产：李浩；中信建投：刘慧彬；博时基金：张涵、付伟、郭康斌、 梁起飞、刘宁、唐亮、王诗瑶、王远征、魏立、叶丽、施永辉、陈西铭； 广发基金：王瑞冬、邱璟旻、梁东旭；易方达基金：杨桢霄、朱明新；天 风证券：杨松、张雪、周海涛；国投证券：马帅、龚涵清；华泰保兴：礼 参与单位名称 晨；鹏华基金：陈璇淼；国寿安保基金：刘志军；信达澳亚：杨珂、李东 及人员姓名 升；富荣基金：曾博文；冲积资产；深圳红筹投资：葛云霄；金鹰基金： 方超；华夏基金：王泽实、陈悦；天弘基金：吕俏；盘京资产：陈勤；建 信基金：马牧青；华鑫证券：胡博鑫、赵冰若；南方基金：史博、秦乾 一；华安证券：谭国超；涌津投资：傅逞强；重阳投资：胡敏；方正富邦 基金：郑森峰；摩根士丹利：潘海洋。 时间 2024年3月4日至2024年3月12日 地点 公司会议室、网络会议 上市公司接待 董事、总经理：张秀杰；市场总监： ...

证券代码：688253 证券简称：英诺特 北京英诺特生物技术股份有限公司 投资者关系活动记录表 编号：2024-003 特定对象调研 □分析师会议 □媒体采访 投资者关系活 □业绩说明会 □新闻发布会 路演活动 动类别 □现场参观 其他（券商策略会等） 国投证券：马帅、龚涵清；国金基金：叶草雨；华宝基金：魏扬帆、易镜 明；东方红：邹秉昂；睿远基金：赵培森；首创证券：王斌；运舟：王 岩、王建礼；东方基金：陈宇、张博；相聚资本：邓巧；南方基金：章 晖、钟赟、秦乾一；融通：王晗、李宏、赵越；浦银安盛：胡攸乔、徐 参与单位名称 博；国泰基金：胡松、王琳、林小聪、邱晓旭；中邮证券：蔡明子；华泰 及人员姓名 证券：高鹏、杨昌源；汇添富：刘丹、马翔、夏僡婕、胡昕炜、黄昀；申 万菱信：付娟、姚宏福、吴琼；国金证券：李润兰；中信保诚基金：杨 强、陈爽、闾志刚；长信基金：陈言午、陈嘉文；浦银安盛：凌晨；磐耀 投资：孙志超；华泰柏瑞基金：张弘；睿亿投资：吕乐艺；硕腾投资：施 嘉锐。 时间 2024年2月27日—2024年3月3日 地点 公司会议室、网络会议、券商策略会 上市公司接待 董事会秘书：陈富康； 人员姓名 市场部：赵 ...